



## Coronary Artery Atherosclerosis: Translation from Basic to Clinic

Dear Colleagues,

Coronary atherosclerosis is one of the leading cause of death in developed countries and one of the most investigated fields in cardiovascular medicine accounting for a huge part of the cost of health systems all over the world. Understanding pathophysiology is heavily linked to the chance of preventing or treat the clinical manifestations of coronary artery disease. New hypotheses and insights from basic science and medicine are currently been investigated or are in the pipeline to be translated into clinical practice. Basic science investigations about the contribution of new markers of disease to development of clinical apparent atherosclerosis are being undertaken in the most advanced centers. Computational and virtual simulation medicine is taking part as one of the newest tools in understanding pathophysiology of the atherosclerotic process and predicting fate of available endovascular therapy. At the same time, new drugs new imaging tools and new interventional techniques and protocols are being developed in order to improve diagnosis, clinical outcomes and prognosis of coronary atherosclerosis. The new special issues of Reviews in Cardiovascular Medicine (ISSN 1530-6550) is aimed to explore this exciting process of translation from basic science to clinical practice in the knowledge, diagnosis and treatment of coronary atherosclerosis.

Dr. Gianluca Rigatelli and Dr. Marco Zuin

### Guest Editor(s):



**Dr. Gianluca Rigatelli**

[jackyheart@libero.it](mailto:jackyheart@libero.it)

Cardiovascular Diagnosis and Endoluminal Interventions, Rovigo General Hospital, Viale Tre Martiri, Rovigo, Italy



**Dr. Marco Zuin**

[zuinml@yahoo.it](mailto:zuinml@yahoo.it)

Department of Translational Medicine, University of Ferrara, Ferrara, Italy



## Message from the Editor-in-Chief

Reviews in Cardiovascular Medicine was launched in 2000 by MedReviews, LLC, in New York, NY. This journal was conceived to fill a critical gap for clinicians who were struggling with a rapidly expanding knowledge base in cardiovascular medicine with the convergence of basic science, clinical epidemiology, and therapeutic clinical trials. The founding co-editors were David P. Faxon, MD, past president of the American Heart Association, and Norman E. Lepor, MD, who is considered a luminary in interventional cardiology. The contributing editorial board grew over time and Dr. Peter A. McCullough, MD, MPH ascended from contributing, to associate, to co-editor of the Journal. In 2018, the Journal took its next big step under the leadership of Dr. McCullough as editor-in-chief to become a truly international publication. Its offices moved to IMR Press in Hong Kong, and the editorial board was made more inclusive and representative of the world-wide contributors in academic cardiology. Additionally, the journal brought on expertise in translational medicine to help face the future of molecular medicine and its role in cardiovascular disease. Today Reviews in Cardiovascular Medicine is considered a top tier journal in cardiology with timely and comprehensive reviews covering all aspects of cardiovascular medicine including atherosclerosis, myocardial disease, arrhythmias, and valvular heart disease. The scope of papers ranges from population science, applied basic investigation, in-vitro diagnostics, and evidence-based strategy and therapeutic trials involving both pharmacologic intervention and interventional devices. The highly integrative style of the Journal anchored with evidence tables and instructive figures has garnered many citations over the years and many guidelines documents have relied upon works published in Reviews in Cardiovascular Medicine. Supplement and focus issues have been very popular among the readership and often are viewed as the most up-to-date compilations of new knowledge in cardiology and related specialties. The future is bright for academic cardiovascular medicine and Reviews in Cardiovascular Medicine is well positioned alongside the clinician-investigator in the years to come as a trusted source of critical information and analysis.

## Editor-in-chief:



**Dr. Peter A. McCullough**

[peteramccullough@gmail.com](mailto:peteramccullough@gmail.com)

Baylor University Medical Center, Baylor Heart and Vascular Institute, Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, TX, United States

**Submission Deadline: 30 March 2022**

**Submission:** <https://jour.ipublishment.com/imr/access/login>

**Contact us:** [RCMeditorial@imrpress.org](mailto:RCMeditorial@imrpress.org)

